var data={"title":"Pneumonia in children: Inpatient treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pneumonia in children: Inpatient treatment</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/contributors\" class=\"contributor contributor_credentials\">William J Barson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/contributors\" class=\"contributor contributor_credentials\">George B Mallory, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 30, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. CAP is a common and potentially serious illness with considerable morbidity.</p><p>The inpatient treatment of CAP and hospital-acquired pneumonia in children will be reviewed here. The outpatient treatment of CAP is discussed separately, as are the epidemiology, etiology, clinical features, and diagnosis. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-outpatient-treatment\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Outpatient treatment&quot;</a> and <a href=\"topic.htm?path=pneumonia-in-children-epidemiology-pathogenesis-and-etiology\" class=\"medical medical_review\">&quot;Pneumonia in children: Epidemiology, pathogenesis, and etiology&quot;</a> and <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;</a>.)</p><p>The recommendations provided below are largely consistent with practice guidelines provided by <a href=\"http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organ_System-81567/Lower/Upper_Respiratory/Community-Acquired_Pneumonia_(CAP)_in_Infants_and_Children/&amp;token=Vwx4Ku8nqWCVUgjqq5gqMX7YND2tgIVBGn8VSs3Dl08zRsZWXKOVqAX1/dxYTEH/QdIwU+HP+/W4erS58Yh8/2FsVy+otCOBQ3qDEAUmo8i+NeVkPzNmZ5c18nmrBFFwyCDfPFDWlVz60c4RBfF5s9umneVwsWj3m30GAsf9SLyPyfADA6whKNrbrbrMeaa9dNRtdMRVhaxVWgREitD/VQ==&amp;TOPIC_ID=6054\" target=\"_blank\" class=\"external\">The Pediatric Infectious Diseases Society/Infectious Diseases Society of America</a> and the <a href=\"https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/community-acquired-pneumonia-in-children-guideline/&amp;token=OU2e24KcAVHK39yFP2v4fI19B28Ilyz1xCRy8UpA5c2CFYpuRH7Dlvf73yxjjeVJpqt+kZoB6icvLUmbnbwCB4QtwIhHZDFeSTj/B1w3TTT0oUX1+azC25xoQTasydu5ID5/eW0nrRwoR78AImOZpA==&amp;TOPIC_ID=6054\" target=\"_blank\" class=\"external\">British Thoracic Society</a> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=society-guideline-links-pediatric-pneumonia\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pediatric pneumonia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">HOSPITALIZATION</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to hospitalize a child with community-acquired pneumonia (CAP) is individualized based upon age, underlying medical problems, and clinical factors including severity of illness (<a href=\"image.htm?imageKey=PEDS%2F72015\" class=\"graphic graphic_table graphicRef72015 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Hospitalization generally is warranted for infants younger than three to six months of age, unless a viral etiology or <em>Chlamydia trachomatis</em> is suspected and they are not hypoxemic and relatively asymptomatic. Hospitalization is also warranted for a child of any age whose family cannot provide appropriate care and assure compliance with the management plan. Additional indications for hospitalization include [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypoxemia (peripheral capillary oxygen saturation [SpO<sub>2</sub>] &lt;90 percent in room air at sea level)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dehydration, or inability to maintain hydration orally; inability to feed in an infant</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate to severe respiratory distress: Respiratory rate &gt;70 <span class=\"nowrap\">breaths/minute</span> for infants &lt;12 months of age and &gt;50 breaths per minute for older children; retractions; nasal flaring; difficulty breathing; apnea; grunting</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxic appearance (more common in bacterial pneumonia and may suggest a more severe course) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4\" class=\"abstract_t\">4</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Underlying conditions that may predispose to a more serious course of pneumonia (eg, cardiopulmonary disease, genetic syndromes, neurocognitive disorders), may be worsened by pneumonia (eg, metabolic disorder) or may adversely affect response to treatment (eg, immunocompromised host)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complications (eg, <span class=\"nowrap\">effusion/empyema,</span> abscess)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suspicion or confirmation that CAP is due to a pathogen with increased virulence, such as <em>Staphylococcus aureus</em> or group A <em>Streptococcus </em>(GAS)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Failure of outpatient therapy (worsening or no response in 48 to 72 hours)</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Indications for intensive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to treat a child with pneumonia in an intensive care setting is individualized, based upon clinical, laboratory, and radiologic findings. Treatment in an intensive care setting generally is warranted for children who manifest [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The need for ventilatory support beyond that which can be provided outside the intensive care unit (eg, mechanical ventilation, noninvasive positive pressure ventilation, failure to maintain SpO<sub>2</sub> &gt;92 percent in fraction of inspired oxygen [FiO<sub>2</sub>] &gt;0.5)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of impending respiratory failure (lethargy, increasing work of breathing, <span class=\"nowrap\">and/or</span> exhaustion with or without hypercarbia)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent apnea or slow irregular respirations</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiovascular compromise with progressive tachycardia <span class=\"nowrap\">and/or</span> hypotension that requires or is refractory to fluid management</p><p/><p>Care in the intensive care unit also may be warranted for children with two or more of the following [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory rate &gt;70 <span class=\"nowrap\">breaths/minute</span> for infants &lt;12 months of age and &gt;50 <span class=\"nowrap\">breaths/minute</span> for older children</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Apnea</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased work of breathing (retractions, dyspnea, nasal flaring, grunting)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Partial pressure of oxygen in arterial blood (PaO<sub>2</sub><span class=\"nowrap\">)/FiO<sub>2</sub></span> ratio &lt;250</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multilobar infiltrates</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered mental status</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotension</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleural effusion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Comorbid condition (eg, sickle cell disease, immune deficiency, immunosuppression)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unexplained metabolic acidosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pediatric Early Warning Score &gt;6 [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/5\" class=\"abstract_t\">5</a>]</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Infection control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CAP can be caused by a variety of microbial agents requiring a variety of infection-control measures [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/6\" class=\"abstract_t\">6</a>]. If possible, rapid diagnostic tests should be performed at the time of admission to facilitate decisions regarding appropriate precautions. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H24\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Rapid diagnostic tests'</a>.)</p><p>Hand washing is the single most important procedure to prevent the spread of infection. Additional infection control measures depend upon the likely pathogen(s), as follows [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/6,7\" class=\"abstract_t\">6,7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory syncytial and parainfluenza viruses &ndash; Gown and gloves (ie, contact precautions)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Influenza virus, GAS (for the first 24 hours of treatment), methicillin-susceptible <em>S. aureus</em>, <em>Bordetella pertussis</em> (until patient has received five days of effective therapy), and <em>Mycoplasma pneumoniae</em> &ndash; Mask within 3 feet (ie, droplet precautions)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adenovirus &ndash; Contact and droplet precautions</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Methicillin-resistant <em>S. aureus </em>and other multidrug resistant organisms &ndash; Special organism precautions; contact and droplet precautions and dedicated patient equipment</p><p/><p>These precautions are discussed separately (see <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>). Guidelines for hand hygiene in health care settings can be accessed through the <a href=\"http://www.cdc.gov/handhygiene/&amp;token=mjmpv7xMHRIW2nr+3NCnsdb6Rm17RL9ekVcdIbLJB6qBfLOKZNVwcvbvSifDbRcy&amp;TOPIC_ID=6054\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention</a>.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">SUPPORTIVE CARE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive care includes ensuring adequate antipyresis, analgesia, respiratory support, and hydration.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Antipyresis and analgesia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children hospitalized with pneumonia usually have fever and may have pleuritic chest pain, which can lead to shallow breathing and impaired ability to cough. Administration of antipyretics <span class=\"nowrap\">and/or</span> analgesics (eg, <a href=\"topic.htm?path=acetaminophen-paracetamol-pediatric-drug-information\" class=\"drug drug_pediatric\">acetaminophen</a>, <a href=\"topic.htm?path=ibuprofen-pediatric-drug-information\" class=\"drug drug_pediatric\">ibuprofen</a>) can be used to keep the child comfortable; opioid analgesia is rarely necessary in children without a chest tube in place. Adequate pain control may promote coughing, which facilitates airway clearance. Antitussives should be avoided as none have been found to be effective in pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/8\" class=\"abstract_t\">8</a>]. Symptomatic treatment of cough is discussed separately. (See <a href=\"topic.htm?path=the-common-cold-in-children-management-and-prevention#H15315058\" class=\"medical medical_review\">&quot;The common cold in children: Management and prevention&quot;, section on 'Cough'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Respiratory support</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children hospitalized with pneumonia should receive ventilatory support as indicated by their clinical condition [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. A supported sitting position may help to expand the lungs and improve respiratory symptoms [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>].</p><p>We suggest that children with oxygen saturation [SpO<sub>2</sub>] &lt;95 percent in room air be treated with supplemental oxygen to maintain oxygen saturation &ge;95 percent while they are in respiratory distress. Different thresholds for supplemental oxygen are suggested by other experts (eg, the British Thoracic Society guidelines suggest supplemental oxygenation to maintain oxygenation saturation &gt;92 percent) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>]. Gentle bulb suction of the nares may be helpful in infants and children whose nares are blocked with secretions. Minimal handling seems to reduce oxygen requirements. (See <a href=\"topic.htm?path=continuous-oxygen-delivery-systems-for-infants-children-and-adults\" class=\"medical medical_review\">&quot;Continuous oxygen delivery systems for infants, children, and adults&quot;</a>.)</p><p>In children who are severely ill, it may be necessary to monitor carbon dioxide tension via blood gas analysis in addition to SpO<sub>2</sub> by oximetry. Hypercarbia is an important sign of impending respiratory failure, particularly in the young infant who is tiring but may have preserved oxygenation.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Fluid management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children who cannot maintain adequate fluid intake because of breathlessness, fatigue, or risk of aspiration [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/9\" class=\"abstract_t\">9</a>] may require intravenous fluid therapy. Nasogastric (NG) tubes should be avoided if possible because they may compromise breathing; if necessary, the smallest NG tube possible should be used [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=maintenance-fluid-therapy-in-children\" class=\"medical medical_review\">&quot;Maintenance fluid therapy in children&quot;</a>.)</p><p>Children with pneumonia are at risk for inappropriate secretion of antidiuretic hormone (SIADH) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/10,11\" class=\"abstract_t\">10,11</a>]. Serum electrolytes, fluid balance, and urine specific gravity should be monitored if there is clinical suspicion of SIADH [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/11\" class=\"abstract_t\">11</a>]. Confirmation of SIADH is discussed separately. Isotonic, rather than hypotonic, intravenous fluids should be provided if SIADH is suspected. (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh#H13\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;, section on 'Pulmonary disease'</a> and <a href=\"topic.htm?path=maintenance-fluid-therapy-in-children#H11\" class=\"medical medical_review\">&quot;Maintenance fluid therapy in children&quot;, section on 'Hospitalized children'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Chest physiotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chest physiotherapy is not beneficial for children with uncomplicated community-acquired pneumonia (CAP) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>]. In randomized and observational studies in children and adults, chest physiotherapy had no conclusive effect on length of hospital stay, duration of fever, or radiographic resolution [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/12-17\" class=\"abstract_t\">12-17</a>].</p><p class=\"headingAnchor\" id=\"H9492623\"><span class=\"h2\">Adjunctive glucocorticoid therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not routinely provide adjunctive glucocorticoid therapy to children hospitalized with pneumonia. Although a systematic review and meta-analysis of two small heterogeneous trials suggested that glucocorticoids reduce clinical failure (defined as death from any cause, radiographic progression, or clinical instability at day 5 to 8) and time to clinical cure, additional studies in children are necessary before glucocorticoids can be routinely recommended [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/18-20\" class=\"abstract_t\">18-20</a>]. A retrospective study evaluating adjunctive glucocorticoid therapy for children being treated for CAP in the outpatient setting found an association between adjunctive glucocorticoid therapy and treatment failure in children without underlying asthma [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Adjunctive glucocorticoids for adults with pneumonia are discussed separately. (See <a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization#H3950330468\" class=\"medical medical_review\">&quot;Treatment of community-acquired pneumonia in adults who require hospitalization&quot;, section on 'Adjunctive glucocorticoids'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">EMPIRIC THERAPY</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prompt initiation of antimicrobial therapy is crucial in children with community-acquired pneumonia (CAP). The initial treatment of children who are hospitalized with pneumonia is empiric (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>). Factors that must be considered include the spectrum of likely pathogens, antimicrobial susceptibility, simplicity, tolerability, palatability, safety, and cost [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/22\" class=\"abstract_t\">22</a>].</p><p>The recommendations of most guidelines are based on in vitro susceptibilities of the most likely pathogen or pathogens, rather than evidence of the superiority of one antibiotic over another. Clinical response to empiric therapy and results of microbiologic studies, when available, help to determine whether additional evaluation or changes in therapy are necessary [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H22\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Microbiology'</a> and <a href=\"#H25\" class=\"local\">'Specific therapy'</a> below and <a href=\"#H31\" class=\"local\">'Response to therapy'</a> below.)</p><p>There are few randomized controlled trials to guide the choice of empiric antibiotics in children with CAP. Decisions regarding empiric therapy are complicated by the substantial overlap in the clinical presentation of bacterial and nonbacterial pneumonias [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/23-25\" class=\"abstract_t\">23-25</a>]. Treatment decisions usually are based upon algorithms that include patient age, epidemiologic and clinical information, and diagnostic laboratory and imaging studies (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4\" class=\"abstract_t\">4</a>]. The scope of empiric therapy (ie, narrow or broad) depends upon the severity of illness and presence of complications. Agents other than those suggested in the table may be more appropriate if there are clinical or epidemiologic features strongly suggestive of a specific cause (eg, mediastinal or hilar lymphadenopathy, residence in the central United States, and exposure to caves <span class=\"nowrap\">and/or</span> bat guano suggestive of pulmonary histoplasmosis).</p><p>Consultation with a specialist in infectious disease may be helpful in children with medication allergies, comorbid conditions, failure of outpatient therapy, or multiple-drug-resistant organisms. Consultation with a pediatric pulmonologist may be helpful in children with recurrent pneumonia. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-outpatient-treatment#H13\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Outpatient treatment&quot;, section on 'Treatment failure'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Etiologic clues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Certain clinical and epidemiologic features can be used to determine the most likely pathogen(s) to aid in decisions regarding empiric therapy. Because these features often overlap, they cannot be used with complete confidence but are helpful in guiding empiric therapy until results of microbiologic tests are available (<a href=\"image.htm?imageKey=PEDS%2F52021\" class=\"graphic graphic_table graphicRef52021 \">table 3</a>). These features are discussed in greater detail separately. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H12\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Clues to etiology'</a> and <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H19\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Etiologic clues'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Neonates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of neonatal pneumonia is discussed separately. (See <a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Viral pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most children younger than three to five years of age who are admitted to the hospital with pneumonia have viral pneumonia (eg, respiratory syncytial virus [RSV]) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/26\" class=\"abstract_t\">26</a>]. This is particularly true in the absence of lobar (or lobular) infiltrate and pleural effusion [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4\" class=\"abstract_t\">4</a>]. Viral pneumonia does not require antibiotic therapy unless a mixed infection or secondary bacterial infection is suspected. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment#H2\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Treatment&quot;, section on 'Overview'</a> and <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis#H15\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Clinical features and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p>No effective antivirals are available for most viral pneumonias, with a few important exceptions, described below.</p><p class=\"headingAnchor\" id=\"H275031\"><span class=\"h3\">Influenza pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initiation of antiviral treatment for influenza (eg, <a href=\"topic.htm?path=oseltamivir-pediatric-drug-information\" class=\"drug drug_pediatric\">oseltamivir</a>) as soon as possible is recommended for children hospitalized with presumed influenza pneumonia; laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H20\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Antiviral therapy'</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-clinical-features-and-diagnosis#H17\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Clinical features and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p>For children with influenza pneumonia in whom secondary bacterial pneumonia is suspected, empiric antibiotic therapy should include coverage for <em>S. aureus</em>, including methicillin-resistant <em>S. aureus</em> (MRSA). Coinfection with <em>S. aureus</em> may be particularly severe and rapidly fatal.</p><p class=\"headingAnchor\" id=\"H164277222\"><span class=\"h3\">Other viral pneumonias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Acyclovir</a> can be used in the treatment of pneumonia due to herpes simplex virus (HSV) or varicella zoster virus (VZV). <a href=\"topic.htm?path=ganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Ganciclovir</a> can be used in the treatment of pneumonia due to cytomegalovirus (CMV). (See <a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection#H252835606\" class=\"medical medical_review\">&quot;Treatment of varicella (chickenpox) infection&quot;, section on 'Individuals with complications'</a>.)</p><p>Common respiratory viruses may cause serious infections in immunocompromised children and require consideration of antiviral therapy: <a href=\"topic.htm?path=ribavirin-pediatric-drug-information\" class=\"drug drug_pediatric\">ribavirin</a> for RSV or parainfluenza and <a href=\"topic.htm?path=cidofovir-pediatric-drug-information\" class=\"drug drug_pediatric\">cidofovir</a> for adenovirus. Concomitant immunoglobulin therapy is an additional consideration: <a href=\"topic.htm?path=palivizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">palivizumab</a> for RSV, CMV <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> for CMV, and intravenous immunoglobulin for the other viral etiologies. (See <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment#H5\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Treatment&quot;, section on 'Pharmacotherapy'</a> and <a href=\"topic.htm?path=diagnosis-treatment-and-prevention-of-adenovirus-infection#H16\" class=\"medical medical_review\">&quot;Diagnosis, treatment, and prevention of adenovirus infection&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Uncomplicated bacterial pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Streptococcus pneumoniae</em> is the most common bacterial cause of pneumonia in children of all ages [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4,27\" class=\"abstract_t\">4,27</a>]. Other potential bacterial pathogens that may need to be included in empiric therapy for hospitalized children include <em>S. aureus</em>, including MRSA, <em>Streptococcus pyogenes</em> (group A <em>Streptococcus</em>), <em>Haemophilus influenzae</em> type b (Hib) (if unimmunized), nontypeable <em>H. influenzae</em>, and <em>Moraxella catarrhalis</em> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2,4,27-32\" class=\"abstract_t\">2,4,27-32</a>].</p><p>The table provides several suggested parenteral empiric antibiotic regimens for <strong>uncomplicated</strong> bacterial pneumonia in hospitalized children when <em>S. aureus</em> is not a consideration (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4,33,34\" class=\"abstract_t\">4,33,34</a>]. The treatment of complicated CAP and severe CAP (particularly when <em>S. aureus</em> is a consideration) are discussed below. (See <a href=\"#H96270984\" class=\"local\">'Complicated CAP'</a> below and <a href=\"#H21\" class=\"local\">'Severe CAP requiring ICU admission'</a> below.)</p><p><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> or <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> generally provides adequate coverage for the fully immunized child (<a href=\"image.htm?imageKey=PEDS%2F95852\" class=\"graphic graphic_table graphicRef95852 \">table 4</a>) in communities without substantial prevalence of penicillin-resistant <em>S. pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,35,36\" class=\"abstract_t\">1,35,36</a>]. We suggest a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a>) for children younger than 12 months and those who are not fully immunized because third-generation cephalosporins provide coverage for the beta-lactamase producing pathogens (eg, <em>H. influenzae </em>and<em> M. catarrhalis</em>) that may occur in these children. We also suggest third-generation cephalosporins for children with more severe illness (<a href=\"image.htm?imageKey=PEDS%2F72015\" class=\"graphic graphic_table graphicRef72015 \">table 1</a>) because third-generation cephalosporins provide coverage for a broader range of pathogens, including penicillin-resistant <em>S. pneumoniae</em>, than ampicillin [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,37,38\" class=\"abstract_t\">1,37,38</a>]. The fifth-generation parenteral cephalosporin, <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftaroline</a>, is approved by the US Food and Drug Administration for treatment of community-acquired bacterial pneumonia due to <em>S. pneumoniae</em>, methicillin-susceptible <em>S. aureus</em> (MSSA), and <em>H. influenzae</em> in children &ge;2 months of age. Although ceftaroline exhibits in vitro activity against MRSA [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/39\" class=\"abstract_t\">39</a>], clinical experience is insufficient to suggest its use when MRSA is a consideration. In a randomized trial in children between 2 months and &lt;18 years who were hospitalized with CAP, ceftaroline and ceftriaxone had similar cure rates [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/40\" class=\"abstract_t\">40</a>]. Three children with <em>S. aureus</em> infection (two with MSSA recovered from sputum and one with MRSA recovered from blood) were successfully treated with ceftaroline. However, patients considered at risk for MRSA infection and those with sputum demonstrating a predominance of gram-positive cocci in clusters were excluded from the trial, precluding conclusions about efficacy in this population.</p><p>A macrolide may be added (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) if <em>M. pneumoniae</em>, <em>Chlamydia pneumoniae</em>, or legionellosis is suspected, although the benefits of combination therapy are uncertain. In a prospective population-based study of 1418 children hospitalized with radiographically confirmed CAP, the addition of a macrolide to beta-lactam antimicrobial therapy was not associated with decreased length of stay, intensive care admission, rehospitalization, or self-reported recovery [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/41\" class=\"abstract_t\">41</a>]. In subgroup analysis, combination therapy was not associated with decreased length of stay in children in whom atypical bacteria were detected, children older than five years, children admitted to the intensive care unit, or children with wheezing. (See <a href=\"#H18\" class=\"local\">'Atypical pneumonia'</a> below.)</p><p>We suggest that children who require hospitalization for treatment of CAP be treated initially with parenteral antibiotics. However, oral <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> may be an alternative for infants and children fully immunized against Hib and <em>S. pneumoniae</em> with uncomplicated pneumonia that is not thought to be due to <em>S. aureus</em>. In a multicenter randomized trial, treatment with amoxicillin was equivalent to treatment with <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> in children with CAP who required hospital admission but did not have wheezing, hypotension, chronic pulmonary conditions (other than asthma), immunodeficiency, pleural effusion requiring drainage, or oxygen saturations &lt;85 percent in room air [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/42\" class=\"abstract_t\">42</a>]. The British Thoracic Society guidelines suggest that oral antibiotics are safe and effective even for children with severe pneumonia as long as they are able to tolerate oral fluids, are not vomiting, and do not have signs of septicemia or complicated pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Atypical pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atypical bacterial pathogens include <em>C. trachomatis</em> in afebrile infants, and <em>M. pneumoniae</em> and <em>C. pneumoniae</em> in older children and adolescents. The table provides several suggested empiric regimens for atypical bacterial pneumonia in hospitalized children (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4,33\" class=\"abstract_t\">4,33</a>].</p><p>For children older than four years with suspected atypical pneumonia, coverage for typical bacterial pathogens (eg, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> or a third-generation cephalosporin) may be added to empiric coverage for atypical pathogens if there is strong evidence of a bacterial cause. Strong evidence of a bacterial cause includes white blood cell count <span class=\"nowrap\">&gt;15,000/microL,</span> C-reactive protein &gt;35 to 60 <span class=\"nowrap\">mg/L</span> (3.5 to 6 <span class=\"nowrap\">mg/dL),</span> chills, or no response to outpatient therapy with a macrolide or <a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">doxycycline</a> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4,43\" class=\"abstract_t\">4,43</a>].</p><p>Fluoroquinolones (eg, <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">levofloxacin</a>, <a href=\"topic.htm?path=moxifloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">moxifloxacin</a>) may be reasonable empiric therapy for the older child and adolescent with suspected atypical pneumonia who could actually have pneumococcal pneumonia. The fluoroquinolones also may be used in the older child or adolescent who has a type 1 hypersensitivity (<a href=\"image.htm?imageKey=PULM%2F80466\" class=\"graphic graphic_table graphicRef80466 \">table 5</a>) to beta-lactam antibiotics. In addition to their excellent gram-negative spectrum, the fluoroquinolones are active against a number of the pathogens responsible for CAP, including beta-lactam-susceptible and nonsusceptible <em>S. pneumoniae</em>, <em>M. pneumoniae </em>(including macrolide-resistant<em> M. pneumoniae)</em>, and <em>C. pneumoniae </em>[<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/44\" class=\"abstract_t\">44</a>]. However, <em>S. pneumoniae</em> resistant to levofloxacin have been identified [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Severe CAP</span></p><p class=\"headingAnchor\" id=\"H687567972\"><span class=\"h3\">Severe CAP not requiring ICU admission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with severe CAP that do not require admission to the intensive care unit (ICU) (<a href=\"image.htm?imageKey=PEDS%2F72015\" class=\"graphic graphic_table graphicRef72015 \">table 1</a>) may benefit from combination empiric therapy with a macrolide and a beta-lactam antibiotic (eg, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> or third-generation cephalosporin) (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>). If <em>S. aureus</em> is an etiologic consideration, addition of either <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, depending upon local susceptibility patterns, is prudent. Combination therapy improves coverage for resistant organisms and mixed <span class=\"nowrap\">bacterial/atypical</span> bacterial infections. Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. Invasive diagnostic testing, including bronchoscopy with bronchoalveolar lavage, may be necessary for specific microbiologic diagnosis. (See <a href=\"#H17\" class=\"local\">'Uncomplicated bacterial pneumonia'</a> above and <a href=\"#H18\" class=\"local\">'Atypical pneumonia'</a> above and <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H27\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Invasive studies'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Severe CAP requiring ICU admission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children who are admitted to the intensive care unit for serious or life-threatening infections require broad-spectrum empiric coverage that addresses potential beta-lactam resistance and community-associated methicillin-resistant <em>S. aureus</em> (CA-MRSA). (See <a href=\"#H4\" class=\"local\">'Indications for intensive care'</a> above.)</p><p>A suggested regimen for such children may include (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/46-48\" class=\"abstract_t\">46-48</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> 40 to 60 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) in three or four divided doses up to a maximum of 4 <span class=\"nowrap\">g/day,</span> <strong>and</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A third-generation cephalosporin (<a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> 150 <span class=\"nowrap\">mg/kg</span> per day IV in four divided doses up to a maximum of 10 <span class=\"nowrap\">g/day</span> <strong>or</strong> <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> 100 <span class=\"nowrap\">mg/kg</span> per day IV in two divided doses up to a maximum dose of 4 <span class=\"nowrap\">g/day),</span> <strong>and</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin</a> 10 <span class=\"nowrap\">mg/kg</span> once per day IV for two days (maximum 500 <span class=\"nowrap\">mg/day),</span> followed by 5 <span class=\"nowrap\">mg/kg</span> once per day IV (maximum 250 <span class=\"nowrap\">mg/day),</span> <strong>and possibly</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> 150 <span class=\"nowrap\">mg/kg</span> per day IV in four divided doses; maximum 12 <span class=\"nowrap\">g/day</span> if <em>S. aureus</em> is likely (methicillin-susceptible <em>S. aureus</em> is more rapidly killed by nafcillin than by <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>), <strong>and possibly</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiviral therapy for influenza, if the child is hospitalized during influenza season; laboratory confirmation of influenza should not delay initiation of antiviral therapy (see <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H20\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Antiviral therapy'</a>)</p><p/><p>This combination is necessary because of reports of treatment failure resulting from treatment of nonsusceptible <em>S. pneumoniae</em> with beta-lactams, notable <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> resistance among <em>S. pneumoniae</em>, and concern for MRSA [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/46\" class=\"abstract_t\">46</a>]. Virtually all strains of MRSA are susceptible to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections#H17\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;, section on 'Pneumonia'</a>.)</p><p>When treating with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, renal function and serum trough levels or dosing to achieve an area under the <span class=\"nowrap\">curve/minimum</span> inhibitory concentration <span class=\"nowrap\">(AUC/MIC)</span> ratio &gt;400 should be monitored in an attempt to assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20 <span class=\"nowrap\">microgram/mL</span> have been suggested to improve clinical outcomes for complicated infections due to <em>S. aureus </em>[<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/48-50\" class=\"abstract_t\">48-50</a>]. Similar trough levels may not be needed in children to achieve an <span class=\"nowrap\">AUC/MIC</span> &gt;400, and further studies are needed to evaluate the clinical effectiveness and safety of these dosing recommendations in children [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/50-55\" class=\"abstract_t\">50-55</a>].</p><p><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is an oxazolidinone antibiotic with activity against gram-positive cocci, including beta-lactam-resistant <em>S. pneumoniae</em> and MRSA. Linezolid could be substituted for <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> in the above regimen. The dose for linezolid is 10 <span class=\"nowrap\">mg/kg</span> per dose (maximum 600 mg); it is administered every eight hours in children younger than 12 years and every 12 hours in children 12 years and older.</p><p class=\"headingAnchor\" id=\"H96270984\"><span class=\"h2\">Complicated CAP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complicated CAP (eg, parapneumonic effusion, lung abscess) requires a broader spectrum of antibiotic coverage if etiologies other than <em>S. pneumoniae</em> are being considered. The expanded spectrum should include coverage for beta-lactam-resistant isolates and CA-MRSA. Coverage for anaerobes and gram-negative organisms also may be necessary for children with lung abscess [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"abstract_t\">56</a>]. Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H2294532\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Complications'</a> and <a href=\"topic.htm?path=management-and-prognosis-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">&quot;Management and prognosis of parapneumonic effusion and empyema in children&quot;</a>.)</p><p>Complicated CAP requires a prolonged course of antimicrobial therapy, usually initiated parenterally [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/57\" class=\"abstract_t\">57</a>]. Appropriate regimens may include [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftriaxone</a> 100 <span class=\"nowrap\">mg/kg</span> IV in two divided doses up to a maximum dose of 4 <span class=\"nowrap\">g/day,</span> <strong>or</strong> <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> 150 <span class=\"nowrap\">mg/kg</span> per day IV in four divided doses up to a maximum of 10 <span class=\"nowrap\">g/day,</span> <strong>plus </strong><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> 30 to 40 <span class=\"nowrap\">mg/kg</span> per day IV in three or four divided doses to a maximum of 1 to 2 <span class=\"nowrap\">g/day</span> if <em>S. aureus</em> or anaerobes are a consideration.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> 40 to 60 <span class=\"nowrap\">mg/kg</span> per day IV in three or four divided doses up to a maximum of 4 <span class=\"nowrap\">g/day</span> is an alternative to <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> if the patient is allergic to clindamycin or if clindamycin-resistant <em>S. aureus</em> is prevalent in the community. The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing vancomycin varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities. When treating with vancomycin, renal function and serum trough levels or dosing to achieve an <span class=\"nowrap\">AUC/MIC</span> ratio of &gt;400 should be monitored in an attempt to assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20 <span class=\"nowrap\">microgram/mL</span> have been suggested to improve clinical outcomes for complicated infections due to <em>S. aureus </em>[<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/48-50\" class=\"abstract_t\">48-50</a>]<em>.</em> Similar trough levels may not be needed in children to achieve an <span class=\"nowrap\">AUC/MIC</span> &gt;400, and further studies are needed to evaluate the clinical effectiveness and safety of these dosing recommendations in children [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/50-55\" class=\"abstract_t\">50-55</a>]<em>.</em> (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections#H20\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;, section on 'MRSA infections'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin-sulbactam</a> 150 to 200 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> component IV in four divided doses (maximum 8 <span class=\"nowrap\">g/day</span> for the ampicillin component) alone may be effective if a lung abscess is thought to be secondary to an aspiration event. (See <a href=\"#H23\" class=\"local\">'Aspiration pneumonia'</a> below.)</p><p/><p>The duration of therapy and other considerations in the management of complicated pneumonia depend upon the type of complication:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Parapneumonic <span class=\"nowrap\">effusion/empyema</strong></span> &ndash; The treatment of parapneumonic effusion and empyema is discussed in detail separately. (See <a href=\"topic.htm?path=management-and-prognosis-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">&quot;Management and prognosis of parapneumonic effusion and empyema in children&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Necrotizing pneumonia</strong> &ndash; Treatment of necrotizing pneumonia requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response but is usually a total of four weeks or two weeks after the patient is afebrile and has improved clinically. Interventional procedures (eg, percutaneous drainage catheter placement) should be performed cautiously in children with necrotizing pneumonia; such procedures increase the risk of complications, such as the development of bronchopleural fistulae [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,58-60\" class=\"abstract_t\">56,58-60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lung abscess</strong> &ndash; Treatment of lung abscess requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response but is usually a total of four weeks or two weeks after the patient is afebrile and has clinical improvement [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/57\" class=\"abstract_t\">57</a>]. The average duration of fever is four to eight days. Eighty to 90 percent of lung abscesses in children resolve with antibiotic therapy alone and spontaneous drainage through the tracheobronchial tree, provided that bronchial obstruction is removed [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/61\" class=\"abstract_t\">61</a>].</p><p/><p class=\"bulletIndent1\">In cases that fail to resolve with antibiotics alone, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit without the increased risk of complications that occurs in children with necrotizing pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,58,62,63\" class=\"abstract_t\">56,58,62,63</a>]. Percutaneous drainage may be warranted in children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"abstract_t\">56</a>]. At least three weeks of IV antibiotic therapy should be delivered before lobectomy is considered for treatment failure [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pneumatocele</strong> &ndash; Most pneumatoceles involute spontaneously [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/65-67\" class=\"abstract_t\">65-67</a>]. However, on occasion, pneumatoceles result in pneumothorax [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Hospital-acquired pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric treatment of hospital-acquired pneumonia should include coverage for <em>S. aureus</em>, Enterobacteriaceae, <em>Pseudomonas aeruginosa</em>, and anaerobes. Acceptable broad spectrum regimens usually include an aminoglycoside (for gram-negative pathogens) and another agent to address gram-positive pathogens and anaerobes (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aminoglycoside (usually <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>; <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies) <strong>plus one of the following</strong>:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">Piperacillin-tazobactam</a> 300 <span class=\"nowrap\">mg/kg</span> per day IV in four divided doses up to a maximum of 12 <span class=\"nowrap\">g/day,</span> <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">Meropenem</a> 60 <span class=\"nowrap\">mg/kg</span> per day IV in three divided doses, up to a maximum of 6 <span class=\"nowrap\">g/day</span> if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies, <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftazidime</a> 125 to 150 <span class=\"nowrap\">mg/kg</span> per day in three divided doses; maximum of 6 <span class=\"nowrap\">g/day,</span> <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefepime</a> 150 <span class=\"nowrap\">mg/kg</span> per day in three divided doses; maximum of 4 <span class=\"nowrap\">g/day,</span> <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> 30 to 40 <span class=\"nowrap\">mg/kg</span> per day in three or four divided doses; maximum 3.6 <span class=\"nowrap\">g/day</span> (for patients with type 1 hypersensitivity (<a href=\"image.htm?imageKey=PULM%2F80466\" class=\"graphic graphic_table graphicRef80466 \">table 5</a>) to beta-lactam antibiotics)</p><p/><p>The combination of <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> and <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a> should be used if extended-spectrum gram-negative rods are a consideration. The combination of amikacin and either meropenem or <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefepime</a> should be used if AmpC beta-lactamase-producing gram-negative rods are a consideration.</p><p>The <span class=\"nowrap\">cephalosporin/aminoglycoside</span> combination lacks anaerobic coverage, so it should <strong>not</strong> be used when aspiration pneumonia is a possibility. (See <a href=\"#H23\" class=\"local\">'Aspiration pneumonia'</a> below.)</p><p><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> should be added to the empiric regimen if MRSA is a consideration. An agent other than <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">piperacillin-tazobactam</a> should be chosen as the second agent, if feasible, when vancomycin is added because the combination of these two drugs has been associated with increased risk of acute kidney injury [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/69\" class=\"abstract_t\">69</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Aspiration pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antibiotic regimens for community-acquired aspiration pneumonia must cover oral anaerobes. Appropriate antibiotic regimens for hospitalized children include [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"abstract_t\">56</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin-sulbactam</a> 150 to 200 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> component IV in four divided doses; maximum 8 <span class=\"nowrap\">g/day</span> of the ampicillin component, <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> 30 to 40 <span class=\"nowrap\">mg/kg</span> per day IV in three or four divided doses to a maximum of 1 to 2 <span class=\"nowrap\">g/day</span> if MRSA etiology is suspected.</p><p/><p>In neurologically compromised older adolescents prone to aspiration events, empiric treatment for CAP with a fluoroquinolone like <a href=\"topic.htm?path=moxifloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">moxifloxacin</a> (400 mg once daily) may be reasonable. Moxifloxacin has activity against anaerobic bacteria, as well as the usual treatable causes of CAP (<em>S. pneumoniae</em>, <em>M. pneumoniae</em>, and <em>C. pneumoniae)</em>.</p><p>Appropriate antibiotic regimens for children with health care-associated aspiration who are known to be colonized with unusual gram-negative pathogens (eg, <em>Klebsiella pneumoniae</em>) include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">Piperacillin-tazobactam</a> 300 <span class=\"nowrap\">mg/kg</span> per day IV in four divided doses up to a maximum of 12 <span class=\"nowrap\">g/day,</span> <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">Meropenem</a> 60 <span class=\"nowrap\">mg/kg</span> per day IV in three divided doses, up to a maximum of 6 <span class=\"nowrap\">g/day</span></p><p/><p><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> should be added to the empiric regimen if MRSA is a consideration. <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">Meropenem</a> may be preferred for gram-negative coverage if vancomycin is added because the combination of vancomycin and <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">piperacillin-tazobactam</a> has been associated with increased risk of acute kidney injury [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/69\" class=\"abstract_t\">69</a>]. However, this risk must be weighed against the development of meropenem resistance, particularly in closed units.</p><p>Patients with true beta-lactam hypersensitivity (ie, type 1 hypersensitivity reaction) (<a href=\"image.htm?imageKey=PULM%2F80466\" class=\"graphic graphic_table graphicRef80466 \">table 5</a>) can be treated with a combination of <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> and an aminoglycoside.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Immunocompromised host</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric treatment for pneumonia in immunocompromised hosts also requires broad-spectrum gram-positive and gram-negative coverage, similar to that required for hospital-acquired pneumonia, with the addition of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> if MRSA is considered, and possibly <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a> for <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>). Empiric regimens may need to be modified once results of cultures and antibiotic susceptibility testing are available. Invasive testing may be required to obtain a satisfactory specimen in such patients (see <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H27\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Invasive studies'</a>). Treatment of CAP in the immunocompromised host should occur in consultation with an infectious disease specialist.</p><p>An aggressive approach to specific microbial diagnosis is indicated in immunocompromised hosts with clinically significant pneumonias. For patients with an endotracheal tube in place, specific microbial diagnosis may involve early flexible bronchoscopy for bronchoalveolar lavage with viral, fungal, and bacterial cultures. Although the protected specimen brush technique has been utilized in some settings, quantitative bacterial cultures are more commonly used to differentiate colonization from true lower respiratory tract infection. (See <a href=\"topic.htm?path=flexible-bronchoscopy-in-adults-indications-and-contraindications#H288135472\" class=\"medical medical_review\">&quot;Flexible bronchoscopy in adults: Indications and contraindications&quot;, section on 'Diagnostic indications'</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia#H2756495\" class=\"medical medical_review\">&quot;Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia&quot;, section on 'Diagnostic evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">SPECIFIC THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once results of microbiologic tests are available, antimicrobial therapy can be directed toward the responsible pathogen or pathogens. Specific antibiotic therapy for bacterial community-acquired pneumonia (CAP) is summarized in the table (<a href=\"image.htm?imageKey=PEDS%2F57150\" class=\"graphic graphic_table graphicRef57150 \">table 6</a>). Specific antimicrobial <span class=\"nowrap\">and/or</span> supportive therapy for the pathogens that commonly cause CAP in children is discussed in the topic reviews listed below.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. pneumoniae</em> (see <a href=\"topic.htm?path=pneumococcal-pneumonia-in-children#H15\" class=\"medical medical_review\">&quot;Pneumococcal pneumonia in children&quot;, section on 'Specific therapy'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. pneumoniae</em> (see <a href=\"topic.htm?path=mycoplasma-pneumoniae-infection-in-children#H21\" class=\"medical medical_review\">&quot;Mycoplasma pneumoniae infection in children&quot;, section on 'Treatment'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>C. pneumoniae</em> (see <a href=\"topic.htm?path=pneumonia-caused-by-chlamydia-species-in-children\" class=\"medical medical_review\">&quot;Pneumonia caused by Chlamydia species in children&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Methicillin-susceptible <em>S. aureus </em>(MSSA) &ndash; MSSA pneumonia may be treated with <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a>, <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a>, or <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefazolin</a> [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,4\" class=\"abstract_t\">1,4</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Methicillin-resistant <em>S. aureus</em> (MRSA) (see <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections#H19\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;, section on 'Definitive therapy'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory syncytial virus (see <a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment\" class=\"medical medical_review\">&quot;Respiratory syncytial virus infection: Treatment&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Influenza (see <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H20\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Antiviral therapy'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Parainfluenza (see <a href=\"topic.htm?path=parainfluenza-viruses-in-children#H12\" class=\"medical medical_review\">&quot;Parainfluenza viruses in children&quot;, section on 'Treatment'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adenovirus (see <a href=\"topic.htm?path=diagnosis-treatment-and-prevention-of-adenovirus-infection#H16\" class=\"medical medical_review\">&quot;Diagnosis, treatment, and prevention of adenovirus infection&quot;, section on 'Treatment'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human metapneumovirus (see <a href=\"topic.htm?path=human-metapneumovirus-infections#H19\" class=\"medical medical_review\">&quot;Human metapneumovirus infections&quot;, section on 'Treatment'</a>)</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">DURATION OF TREATMENT</span></p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Parenteral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are few data to guide decisions about the duration of parenteral therapy for community-acquired pneumonia (CAP) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2,70\" class=\"abstract_t\">2,70</a>]. It is common to switch to oral therapy in patients who have received parenteral antibiotics when the patient has become afebrile for 24 to 48 hours and is not having emesis [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/71\" class=\"abstract_t\">71</a>].</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Total duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are few randomized controlled trials to guide decisions about the appropriate duration of antimicrobial therapy for radiographically confirmed childhood pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"abstract_t\">2</a>]. Clinical practice assigns duration of therapy according to the host, causative agent, and severity.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h3\">Uncomplicated cases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual duration of combined parenteral and oral therapy for uncomplicated pneumonia is 7 to 10 days [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Some authorities suggest continuing oral therapy at least one week beyond resolution of fever; others suggest treating until the erythrocyte sedimentation rate falls below 20 <span class=\"nowrap\">mm/hour</span>. Some data from trials in adults suggest that a shorter course may be equivalent to a 7- to 10-day course, but additional controlled studies are necessary before this practice can be recommended routinely for children [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,72-74\" class=\"abstract_t\">56,72-74</a>].</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h3\">Complicated cases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of complications, such as necrotizing pneumonia and lung abscess, requires a prolonged course of antibiotic therapy, usually initiated parenterally. The duration is determined by the clinical response but usually is either a total of four weeks or a total of two weeks after the patient is afebrile and has improved clinically. (See <a href=\"#H96270984\" class=\"local\">'Complicated CAP'</a> above.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">RESPONSE TO THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following clinical parameters can be monitored to assess response to treatment [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Temperature</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory rate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heart rate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peripheral capillary oxygen saturation (SpO<sub>2</sub>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Work of breathing (eg, retractions, nasal flaring, grunting)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest examination (extent of abnormal or absent breath sounds; extent of dullness to percussion)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mental status</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ability to maintain oral intake and hydration</p><p/><p>The frequency of monitoring depends upon the severity of illness. In patients who are receiving oxygen supplementation, oxygen saturation should be evaluated regularly. Evaluation for hypercarbia may be necessary in children with severe respiratory distress, as oxygenation may be preserved.</p><p>The respiratory status of children with community-acquired pneumonia who are appropriately treated should improve within 48 to 72 hours [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1\" class=\"abstract_t\">1</a>]. However, fevers may persist for several days after initiation of appropriate therapy [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h2\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In children who fail to improve as anticipated, the following possibilities must be considered [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,2,75,76\" class=\"abstract_t\">1,2,75,76</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alternative or coincident diagnoses (eg, foreign body aspiration) (see <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H33\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ineffective antibiotic coverage (lack of coverage for the actual etiology or resistant organism)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Development of complications (see <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H2294532\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Underlying immunodeficiency condition</p><p/><p>The history should be reviewed with special attention to the possibility of foreign body aspiration and geographic or environmental exposures associated with pathogens not treated by the empiric regimen (<a href=\"image.htm?imageKey=PEDS%2F52510\" class=\"graphic graphic_table graphicRef52510 \">table 7</a>).</p><p>Changes in laboratory parameters (eg, peripheral white blood cell count, inflammatory markers [if obtained initially]) may provide information about disease progression. Repeat radiographs or additional imaging studies can help to assess the degree of parenchymal involvement and evaluate for complications or anatomic abnormalities [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H2294532\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Complications'</a> and <a href=\"topic.htm?path=pneumonia-in-children-epidemiology-pathogenesis-and-etiology#H14\" class=\"medical medical_review\">&quot;Pneumonia in children: Epidemiology, pathogenesis, and etiology&quot;, section on 'Etiologic agents'</a>.)</p><p>Depending upon the severity of illness, more aggressive attempts may need to be made to establish a microbiologic diagnosis (eg, induced sputum [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/77\" class=\"abstract_t\">77</a>], bronchoscopy with bronchoalveolar lavage, percutaneous needle aspiration, or lung biopsy). In children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,58,62,63\" class=\"abstract_t\">56,58,62,63</a>]. (See <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis#H27\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;, section on 'Invasive studies'</a>.)</p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h1\">DISCHARGE CRITERIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Discharge criteria for children who have been admitted to the hospital with community-acquired pneumonia (CAP) have not been standardized, but typically include [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1,56\" class=\"abstract_t\">1,56</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement of vital signs</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ability to maintain adequate fluid and nutrition orally</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ability to maintain oxygen saturation &ge;90 percent in room air</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in respiratory status</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overall clinical improvement including level of activity, appetite, and decreased fever for at least 12 to 24 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stable <span class=\"nowrap\">and/or</span> baseline mental status</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Parents' ability to administer and child's ability to comply with home antibiotic regimen</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Safe and compliant home environment</p><p/><p class=\"headingAnchor\" id=\"H34\"><span class=\"h2\">Outpatient parenteral antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Outpatient parenteral antimicrobial therapy (OPAT) is an option for selected patients who require prolonged treatment (usually for complicated CAP that for some reason cannot be treated with an oral antibiotic) and have stabilized clinically [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,78,79\" class=\"abstract_t\">56,78,79</a>]. Eligibility for OPAT requires a suitable home environment and a pharmacologic agent with a reasonable dosing schedule [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/80\" class=\"abstract_t\">80</a>]. Decisions regarding OPAT should involve the caregivers, an infectious disease specialist (or clinician knowledgeable about the use of antimicrobial agents in OPAT), a hospital pharmacist, and the primary care provider. The services of a visiting nurse may be required for home visits, education and observation of caregiver administration, <span class=\"nowrap\">and/or</span> obtaining blood samples for therapeutic monitoring.</p><p class=\"headingAnchor\" id=\"H35\"><span class=\"h1\">FOLLOW-UP</span></p><p class=\"headingAnchor\" id=\"H36\"><span class=\"h2\">Clinical course</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with pneumonia should be seen by their primary care provider soon after discharge to ensure that clinical improvement continues and antibiotic therapy is being taken as prescribed [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"abstract_t\">56</a>]. Decisions regarding the timing of clinical follow-up should involve the child's primary care provider and the clinical status of the child at the time of discharge.</p><p>Children who are appropriately treated for pneumonia should gradually improve with time. Cough may persist for as long as three to four months after viral pneumonia or pertussis. Children who are recovering from typical or atypical bacterial pneumonia may continue to cough for several weeks and have moderate dyspnea on exertion for two to three months [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/81\" class=\"abstract_t\">81</a>]. Symptomatic treatment of cough is discussed separately. (See <a href=\"topic.htm?path=the-common-cold-in-children-management-and-prevention#H15315058\" class=\"medical medical_review\">&quot;The common cold in children: Management and prevention&quot;, section on 'Cough'</a>.)</p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h2\">Radiographs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Follow-up radiographs are not necessary in asymptomatic children with uncomplicated community-acquired pneumonia (CAP), including round pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/82\" class=\"abstract_t\">82</a>]. However, in children with complicated CAP or CAP that required intervention, follow-up radiographs help to ensure resolution [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2,83\" class=\"abstract_t\">2,83</a>]. Follow-up radiographs also may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2,56,84\" class=\"abstract_t\">2,56,84</a>]. When follow-up radiographs are indicated, they should be obtained two to three weeks after hospital discharge [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,85\" class=\"abstract_t\">56,85</a>].</p><p>Several studies have evaluated the utility of follow-up radiographs in cohorts of children with acute radiologically proven CAP [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/86-91\" class=\"abstract_t\">86-91</a>]. Three of the studies included clinical as well as radiologic follow-up at three to seven weeks after initial diagnosis [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/86-89\" class=\"abstract_t\">86-89</a>]. In each of these studies, follow-up radiographs were normal or improved in asymptomatic children. Residual radiographic findings, even when present, did not result in additional therapy. In a literature review [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/82\" class=\"abstract_t\">82</a>], follow-up radiographs (when obtained) were also normal in children with round pneumonia who responded appropriately to antibiotic therapy [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/92-96\" class=\"abstract_t\">92-96</a>]; one child with persistent symptoms was diagnosed with a pulmonary arteriovenous malformation [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/97\" class=\"abstract_t\">97</a>]. Other conditions that should be considered if symptoms persist in children with round pneumonia include congenital lung sequestration, metastatic Wilms tumor, cavitary necrosis, pleural pseudocyst, and primary lung carcinoma [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/84,92,98-100\" class=\"abstract_t\">84,92,98-100</a>].</p><p class=\"headingAnchor\" id=\"H38\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most otherwise healthy children with pneumonia recover without sequelae, even if the pneumonia is complicated [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56,59,60,101\" class=\"abstract_t\">56,59,60,101</a>]. In a multicenter cohort study, approximately 3 percent of 82,566 children hospitalized with pneumonia were readmitted with pneumonia within 30 days of discharge; 8 percent were readmitted for any reason. Readmission was more common among children younger than one year and children with chronic medical conditions [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/102\" class=\"abstract_t\">102</a>].</p><p>Although some data suggest that nearly one-half of children who are hospitalized for viral pneumonia have symptoms of asthma five years after hospitalization, it is not clear whether this is related to unrecognized asthma at the time of presentation with pneumonia or a tendency to develop asthma after community-acquired viral pneumonia [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/103,104\" class=\"abstract_t\">103,104</a>].</p><p>The overall pneumonia mortality rate in developed countries is &lt;1 per 1000 per year [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/26,105\" class=\"abstract_t\">26,105</a>]. Pneumococcal pneumonia case fatality rates (not adjusted for comorbid conditions) for children in the United States were estimated to be 4 percent in children younger than two years and 2 percent in children 2 to 17 years before the introduction of pneumococcal conjugate vaccines [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/106\" class=\"abstract_t\">106</a>].</p><p>The introduction of pneumococcal conjugate vaccines has resulted in a dramatic reduction (37 to 80 percent) in invasive disease and mortality rates in the countries in which they have been introduced [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/107\" class=\"abstract_t\">107</a>]. However, pneumococcal pneumonia mortality rates have not been specifically examined. Data from the United States Pediatric Multicenter Pneumococcal Surveillance Study Group demonstrated overall pneumococcal mortality rates of 1 percent after the introduction of PCV7 (during 2006 to 2009) and 0 percent after the introduction of PCV13 (during 2011 to 2014) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/108\" class=\"abstract_t\">108</a>]. In a study from eastern Gambia, introduction of a nine-valent pneumococcal conjugate vaccine resulted in reduced all-cause mortality (25.2 versus 30.1 per 1000 child-years, a 16 percent reduction) [<a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/109\" class=\"abstract_t\">109</a>]. (See <a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children#H8\" class=\"medical medical_review\">&quot;Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children&quot;, section on 'Efficacy and effectiveness'</a>.)</p><p class=\"headingAnchor\" id=\"H2762175865\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-pediatric-pneumonia\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pediatric pneumonia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=pneumonia-in-children-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Pneumonia in children (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H39\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The decision to hospitalize a child with community-acquired pneumonia (CAP) must be individualized and is based upon age, underlying medical problems, and severity of illness (<a href=\"image.htm?imageKey=PEDS%2F72015\" class=\"graphic graphic_table graphicRef72015 \">table 1</a>). (See <a href=\"#H3\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CAP can be caused by a variety of microbial agents requiring a variety of infection-control measures. (See <a href=\"#H5\" class=\"local\">'Infection control'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supportive care for children hospitalized with pneumonia includes provision of adequate respiratory support, hydration, antipyresis, and analgesia. (See <a href=\"#H6\" class=\"local\">'Supportive care'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with CAP who are hospitalized are treated empirically until information from the microbiologic evaluation is available to direct therapy toward a specific pathogen. Decisions regarding empiric antimicrobial therapy for CAP in children are usually based upon age unless there are other overriding epidemiologic or clinical factors to suggest a specific etiologic agent (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>). (See <a href=\"#H13\" class=\"local\">'Overview'</a> above and <a href=\"topic.htm?path=pneumonia-in-children-epidemiology-pathogenesis-and-etiology#H14\" class=\"medical medical_review\">&quot;Pneumonia in children: Epidemiology, pathogenesis, and etiology&quot;, section on 'Etiologic agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that empiric antibiotic therapy for presumed bacterial pneumonia in hospitalized children include coverage for <em>Streptococcus pneumoniae</em> (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H17\" class=\"local\">'Uncomplicated bacterial pneumonia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extended empiric coverage may be indicated for children with complicated or severe pneumonia, particularly those who require admission to an intensive care unit (<a href=\"image.htm?imageKey=PEDS%2F56260\" class=\"graphic graphic_table graphicRef56260 \">table 2</a>). (See <a href=\"#H96270984\" class=\"local\">'Complicated CAP'</a> above and <a href=\"#H21\" class=\"local\">'Severe CAP requiring ICU admission'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When results of microbiologic tests are available, antibiotic therapy can be directed toward the specific pathogen recovered (<a href=\"image.htm?imageKey=PEDS%2F57150\" class=\"graphic graphic_table graphicRef57150 \">table 6</a>). (See <a href=\"#H25\" class=\"local\">'Specific therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral therapy typically is initiated when the patient has been afebrile for 24 to 48 hours and can tolerate oral intake. The total duration of antibiotic therapy is usually 7 to 10 days for uncomplicated CAP and up to four weeks in complicated CAP. (See <a href=\"#H26\" class=\"local\">'Duration of treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The respiratory status of children receiving appropriate therapy for CAP should improve within 48 to 72 hours. Children who fail to improve as anticipated may be receiving inadequate antibiotic therapy, have developed complications, or have an alternative or coincident diagnosis. (See <a href=\"#H32\" class=\"local\">'Treatment failure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children recovering from CAP may continue to have cough for several weeks to four months, depending upon the etiology. Those recovering from typical or atypical bacterial pneumonia may have moderate dyspnea on exertion for two to three months. (See <a href=\"#H36\" class=\"local\">'Clinical course'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Follow-up radiographs are not necessary in asymptomatic children with uncomplicated CAP. However, in children with complicated CAP or CAP that required intervention, follow-up radiographs help to ensure resolution. Follow-up radiographs two to three weeks after completion of therapy may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates. (See <a href=\"#H37\" class=\"local\">'Radiographs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most otherwise healthy children who develop pneumonia recover without any long-term sequelae. (See <a href=\"#H38\" class=\"local\">'Prognosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/1\" class=\"nounderline abstract_t\">Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/2\" class=\"nounderline abstract_t\">Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/3\" class=\"nounderline abstract_t\">Russell G. Community acquired pneumonia. Arch Dis Child 2001; 85:445.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/4\" class=\"nounderline abstract_t\">McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/5\" class=\"nounderline abstract_t\">Duncan H, Hutchison J, Parshuram CS. The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children. J Crit Care 2006; 21:271.</a></li><li class=\"breakAll\">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. http://www.cdc.gov/hicpac/2007ip/2007isolationprecautions.html (Accessed on September 25, 2011).</li><li class=\"breakAll\">Siegel JD, Rhinehart E, Jackson M, Chiarello, L. Management of multidrug-resistant organisms in healthcare settings, 2006. http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf (Accessed on July 17, 2013).</li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/8\" class=\"nounderline abstract_t\">Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 2014; :CD006088.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/9\" class=\"nounderline abstract_t\">Khoshoo V, Edell D. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics 1999; 104:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/10\" class=\"nounderline abstract_t\">Singhi S, Dhawan A. Frequency and significance of electrolyte abnormalities in pneumonia. Indian Pediatr 1992; 29:735.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/11\" class=\"nounderline abstract_t\">Dhawan A, Narang A, Singhi S. Hyponatraemia and the inappropriate ADH syndrome in pneumonia. Ann Trop Paediatr 1992; 12:455.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/12\" class=\"nounderline abstract_t\">Britton S, Bejstedt M, Vedin L. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 290:1703.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/13\" class=\"nounderline abstract_t\">Levine A. Chest physical therapy for children with pneumonia. J Am Osteopath Assoc 1978; 78:122.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/14\" class=\"nounderline abstract_t\">Stapleton T. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 291:143.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/15\" class=\"nounderline abstract_t\">Paludo C, Zhang L, Lincho CS, et al. Chest physical therapy for children hospitalised with acute pneumonia: a randomised controlled trial. Thorax 2008; 63:791.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/16\" class=\"nounderline abstract_t\">Lukrafka JL, Fuchs SC, Fischer GB, et al. Chest physiotherapy in paediatric patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Arch Dis Child 2012; 97:967.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/17\" class=\"nounderline abstract_t\">Chaves GS, Fregonezi GA, Dias FA, et al. Chest physiotherapy for pneumonia in children. Cochrane Database Syst Rev 2013; :CD010277.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/18\" class=\"nounderline abstract_t\">Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2014; 49:377.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/19\" class=\"nounderline abstract_t\">Nagy B, Gaspar I, Papp A, et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatr Pulmonol 2013; 48:168.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/20\" class=\"nounderline abstract_t\">Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017; 12:CD007720.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/21\" class=\"nounderline abstract_t\">Ambroggio L, Test M, Metlay JP, et al. Adjunct Systemic Corticosteroid Therapy in Children With Community-Acquired Pneumonia in the Outpatient Setting. J Pediatric Infect Dis Soc 2015; 4:21.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/22\" class=\"nounderline abstract_t\">Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004; 43:135.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/23\" class=\"nounderline abstract_t\">Friis B, Andersen P, Bren&oslash;e E, et al. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. Arch Dis Child 1984; 59:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/24\" class=\"nounderline abstract_t\">Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/25\" class=\"nounderline abstract_t\">Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57:438.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/26\" class=\"nounderline abstract_t\">Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/27\" class=\"nounderline abstract_t\">Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/28\" class=\"nounderline abstract_t\">Juv&eacute;n T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19:293.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/29\" class=\"nounderline abstract_t\">Korppi M, Heiskanen-Kosma T, Jalonen E, et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 1993; 152:24.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/30\" class=\"nounderline abstract_t\">Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J 1998; 17:986.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/31\" class=\"nounderline abstract_t\">Trujillo M, McCracken GH Jr. Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia. Pediatr Infect Dis J 1994; 13:411.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/32\" class=\"nounderline abstract_t\">Drummond P, Clark J, Wheeler J, et al. Community acquired pneumonia--a prospective UK study. Arch Dis Child 2000; 83:408.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/33\" class=\"nounderline abstract_t\">Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr Infect Dis J 2002; 21:592.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.871.</li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/35\" class=\"nounderline abstract_t\">Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics 2014; 133:e23.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/36\" class=\"nounderline abstract_t\">Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/37\" class=\"nounderline abstract_t\">Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998; 132:174.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/38\" class=\"nounderline abstract_t\">Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999; 29:462.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/39\" class=\"nounderline abstract_t\">Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. Pediatr Infect Dis J 2017; 36:486.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/40\" class=\"nounderline abstract_t\">Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J 2016; 35:752.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/41\" class=\"nounderline abstract_t\">Williams DJ, Edwards KM, Self WH, et al. Effectiveness of &beta;-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia. JAMA Pediatr 2017; 171:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/42\" class=\"nounderline abstract_t\">Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax 2007; 62:1102.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/43\" class=\"nounderline abstract_t\">Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. Pediatr Infect Dis J 2008; 27:95.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/44\" class=\"nounderline abstract_t\">Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/45\" class=\"nounderline abstract_t\">Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/46\" class=\"nounderline abstract_t\">Kaplan SL, Mason EO Jr, Barson WJ, et al. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001; 20:392.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/47\" class=\"nounderline abstract_t\">Bradley JS. Old and new antibiotics for pediatric pneumonia. Semin Respir Infect 2002; 17:57.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/48\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/49\" class=\"nounderline abstract_t\">Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/50\" class=\"nounderline abstract_t\">McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/51\" class=\"nounderline abstract_t\">Moffett BS, Kim S, Edwards M. Vancomycin nephrotoxicity may be overstated. J Pediatr 2011; 158:865.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/52\" class=\"nounderline abstract_t\">Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 &mu;g/ml in a pediatric intensive care unit. Pharmacotherapy 2013; 33:392.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/53\" class=\"nounderline abstract_t\">Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J 2013; 32:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/54\" class=\"nounderline abstract_t\">Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children wtih suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc 2013; 2:259.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/55\" class=\"nounderline abstract_t\">Patel K, Crumby AS, Maples HD. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? Paediatr Drugs 2015; 17:97.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/56\" class=\"nounderline abstract_t\">Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.</a></li><li class=\"breakAll\">Mani CS. Acute pneumonia and its complications. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.238.</li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/58\" class=\"nounderline abstract_t\">Hoffer FA, Bloom DA, Colin AA, Fishman SJ. Lung abscess versus necrotizing pneumonia: implications for interventional therapy. Pediatr Radiol 1999; 29:87.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/59\" class=\"nounderline abstract_t\">Kerem E, Bar Ziv Y, Rudenski B, et al. Bacteremic necrotizing pneumococcal pneumonia in children. Am J Respir Crit Care Med 1994; 149:242.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/60\" class=\"nounderline abstract_t\">McCarthy VP, Patamasucon P, Gaines T, Lucas MA. Necrotizing pneumococcal pneumonia in childhood. Pediatr Pulmonol 1999; 28:217.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/61\" class=\"nounderline abstract_t\">Tan TQ, Seilheimer DK, Kaplan SL. Pediatric lung abscess: clinical management and outcome. Pediatr Infect Dis J 1995; 14:51.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/62\" class=\"nounderline abstract_t\">Rice TW, Ginsberg RJ, Todd TR. Tube drainage of lung abscesses. Ann Thorac Surg 1987; 44:356.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/63\" class=\"nounderline abstract_t\">Zuhdi MK, Spear RM, Worthen HM, Peterson BM. Percutaneous catheter drainage of tension pneumatocele, secondarily infected pneumatocele, and lung abscess in children. Crit Care Med 1996; 24:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/64\" class=\"nounderline abstract_t\">Emanuel B, Shulman ST. Lung abscess in infants and children. Clin Pediatr (Phila) 1995; 34:2.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/65\" class=\"nounderline abstract_t\">Kunyoshi V, Cataneo DC, Cataneo AJ. Complicated pneumonias with empyema and/or pneumatocele in children. Pediatr Surg Int 2006; 22:186.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/66\" class=\"nounderline abstract_t\">Ceruti E, Contreras J, Neira M. Staphylococcal pneumonia in childhood. Long-term follow-up including pulmonary function studies. Am J Dis Child 1971; 122:386.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/67\" class=\"nounderline abstract_t\">Soto M, Demis T, Landau LI. Pulmonary function following staphylococcal pneumonia in children. Aust Paediatr J 1983; 19:172.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/68\" class=\"nounderline abstract_t\">Amitai I, Mogle P, Godfrey S, Aviad I. Pneumatocele in infants and children. Report of 12 cases. Clin Pediatr (Phila) 1983; 22:420.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/69\" class=\"nounderline abstract_t\">Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/70\" class=\"nounderline abstract_t\">Lassi ZS, Imdad A, Bhutta ZA. Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Cochrane Database Syst Rev 2017; 10:CD008032.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/71\" class=\"nounderline abstract_t\">Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl 3:43.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/72\" class=\"nounderline abstract_t\">Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/73\" class=\"nounderline abstract_t\">Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003; 37:761.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/74\" class=\"nounderline abstract_t\">Uranga A, Espa&ntilde;a PP, Bilbao A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med 2016; 176:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/75\" class=\"nounderline abstract_t\">Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med 2004; 98:488.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/76\" class=\"nounderline abstract_t\">Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/77\" class=\"nounderline abstract_t\">Lahti E, Peltola V, Waris M, et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax 2009; 64:252.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/78\" class=\"nounderline abstract_t\">Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97:28.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/79\" class=\"nounderline abstract_t\">Esposito S. Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy. Chemotherapy 2001; 47 Suppl 1:33.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/80\" class=\"nounderline abstract_t\">Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38:1651.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/81\" class=\"nounderline abstract_t\">Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/82\" class=\"nounderline abstract_t\">McCrossan P, McNaughten B, Shields M, Thompson A. Is follow up chest X-ray required in children with round pneumonia? Arch Dis Child 2017; 102:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/83\" class=\"nounderline abstract_t\">Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/84\" class=\"nounderline abstract_t\">Griscom NT. Pneumonia in children and some of its variants. Radiology 1988; 167:297.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/85\" class=\"nounderline abstract_t\">Donnelly LF. Maximizing the usefulness of imaging in children with community-acquired pneumonia. AJR Am J Roentgenol 1999; 172:505.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/86\" class=\"nounderline abstract_t\">Grossman LK, Wald ER, Nair P, Papiez J. Roentgenographic follow-up of acute pneumonia in children. Pediatrics 1979; 63:30.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/87\" class=\"nounderline abstract_t\">Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005; 40:223.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/88\" class=\"nounderline abstract_t\">Gibson NA, Hollman AS, Paton JY. Value of radiological follow up of childhood pneumonia. BMJ 1993; 307:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/89\" class=\"nounderline abstract_t\">Heaton P, Arthur K. The utility of chest radiography in the follow-up of pneumonia. N Z Med J 1998; 111:315.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/90\" class=\"nounderline abstract_t\">Wacogne I, Negrine RJ. Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Arch Dis Child 2003; 88:457.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/91\" class=\"nounderline abstract_t\">Sur&eacute;n P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008; 97:46.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/92\" class=\"nounderline abstract_t\">Kim YW, Donnelly LF. Round pneumonia: imaging findings in a large series of children. Pediatr Radiol 2007; 37:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/93\" class=\"nounderline abstract_t\">Fretzayas A, Moustaki M, Alexopoulou E, et al. Observations in febrile children with round air space opacities. Pediatr Int 2010; 52:444.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/94\" class=\"nounderline abstract_t\">Celebi S, Hacimustafaoglu M. Round pneumonia in children. Indian J Pediatr 2008; 75:523.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/95\" class=\"nounderline abstract_t\">Karabouta Z, Arampatzi M, Athanassiadou-Piperopoulou F. Single pulmonary round mass in a 12-year-old boy. BMJ Case Rep 2012; 2012.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/96\" class=\"nounderline abstract_t\">Liu YL, Wu PS, Tsai LP, Tsai WH. Pediatric round pneumonia. Pediatr Neonatol 2014; 55:491.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/97\" class=\"nounderline abstract_t\">Bentur H, Harave S. The value of repeat chest radiograph in a child with pneumonia. Arch Dis Child 2012; 97:A186.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/98\" class=\"nounderline abstract_t\">McLennan MK. Radiology rounds. Round pneumonia. Can Fam Physician 1998; 44:751, 757.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/99\" class=\"nounderline abstract_t\">Eggli KD, Newman B. Nodules, masses, and pseudomasses in the pediatric lung. Radiol Clin North Am 1993; 31:651.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/100\" class=\"nounderline abstract_t\">Rose RW, Ward BH. Spherical pneumonias in children simulating pulmonary and mediastinal masses. Radiology 1973; 106:179.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/101\" class=\"nounderline abstract_t\">Bruckheimer E, Dolberg S, Shlesinger Y, et al. Primary lung abscess in infancy. Pediatr Pulmonol 1995; 19:188.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/102\" class=\"nounderline abstract_t\">Neuman MI, Hall M, Gay JC, et al. Readmissions among children previously hospitalized with pneumonia. Pediatrics 2014; 134:100.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/103\" class=\"nounderline abstract_t\">Clark CE, Coote JM, Silver DA, Halpin DM. Asthma after childhood pneumonia: six year follow up study. BMJ 2000; 320:1514.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/104\" class=\"nounderline abstract_t\">Eastham KM, Hammal DM, Parker L, Spencer DA. A follow-up study of children hospitalised with community-acquired pneumonia. Arch Dis Child 2008; 93:755.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/105\" class=\"nounderline abstract_t\">Wu J, Yang S, Cao Q, et al. Pneumonia Mortality in Children Aged &lt;5 Years in 56 Countries: A Retrospective Analysis of Trends from 1960 to 2012. Clin Infect Dis 2017; 65:1721.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/106\" class=\"nounderline abstract_t\">Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223.</a></li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/107\" class=\"nounderline abstract_t\">Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501.</a></li><li class=\"breakAll\">Olarte L, Barson WJ, Barson RM, et al. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era (abstract). 9th World Congress of The World Society for Pediatric Infectious Diseases (WSPID), Rio de Janeiro, Brazil. November 2015. </li><li><a href=\"https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment/abstract/109\" class=\"nounderline abstract_t\">Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6054 Version 52.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H39\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">HOSPITALIZATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Indications</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Indications for intensive care</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Infection control</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">SUPPORTIVE CARE</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Antipyresis and analgesia</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Respiratory support</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Fluid management</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Chest physiotherapy</a></li><li><a href=\"#H9492623\" id=\"outline-link-H9492623\">Adjunctive glucocorticoid therapy</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">EMPIRIC THERAPY</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Overview</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Etiologic clues</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Neonates</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Viral pneumonia</a><ul><li><a href=\"#H275031\" id=\"outline-link-H275031\">- Influenza pneumonia</a></li><li><a href=\"#H164277222\" id=\"outline-link-H164277222\">- Other viral pneumonias</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">Uncomplicated bacterial pneumonia</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Atypical pneumonia</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Severe CAP</a><ul><li><a href=\"#H687567972\" id=\"outline-link-H687567972\">- Severe CAP not requiring ICU admission</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Severe CAP requiring ICU admission</a></li></ul></li><li><a href=\"#H96270984\" id=\"outline-link-H96270984\">Complicated CAP</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Hospital-acquired pneumonia</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Aspiration pneumonia</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Immunocompromised host</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">SPECIFIC THERAPY</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">DURATION OF TREATMENT</a><ul><li><a href=\"#H27\" id=\"outline-link-H27\">Parenteral therapy</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Total duration</a><ul><li><a href=\"#H29\" id=\"outline-link-H29\">- Uncomplicated cases</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">- Complicated cases</a></li></ul></li></ul></li><li><a href=\"#H31\" id=\"outline-link-H31\">RESPONSE TO THERAPY</a><ul><li><a href=\"#H32\" id=\"outline-link-H32\">Treatment failure</a></li></ul></li><li><a href=\"#H33\" id=\"outline-link-H33\">DISCHARGE CRITERIA</a><ul><li><a href=\"#H34\" id=\"outline-link-H34\">Outpatient parenteral antibiotic therapy</a></li></ul></li><li><a href=\"#H35\" id=\"outline-link-H35\">FOLLOW-UP</a><ul><li><a href=\"#H36\" id=\"outline-link-H36\">Clinical course</a></li><li><a href=\"#H37\" id=\"outline-link-H37\">Radiographs</a></li></ul></li><li><a href=\"#H38\" id=\"outline-link-H38\">PROGNOSIS</a></li><li><a href=\"#H2762175865\" id=\"outline-link-H2762175865\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H8578304\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H39\" id=\"outline-link-H39\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6054|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/72015\" class=\"graphic graphic_table\">- Severity of community-acquired pneumonia in infants and children</a></li><li><a href=\"image.htm?imageKey=PEDS/56260\" class=\"graphic graphic_table\">- Empiric IV rx pneumonia in children</a></li><li><a href=\"image.htm?imageKey=PEDS/52021\" class=\"graphic graphic_table\">- Etiologic clues to pediatric pneumonia</a></li><li><a href=\"image.htm?imageKey=PEDS/95852\" class=\"graphic graphic_table\">- Full Hib and pneumococcal immunization status</a></li><li><a href=\"image.htm?imageKey=PULM/80466\" class=\"graphic graphic_table\">- Gell and Coombs classification of immunologic drug reactions</a></li><li><a href=\"image.htm?imageKey=PEDS/57150\" class=\"graphic graphic_table\">- Specific rx pneumonia children</a></li><li><a href=\"image.htm?imageKey=PEDS/52510\" class=\"graphic graphic_table\">- Important aspects of the history in a child with pneumonia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia\" class=\"medical medical_review\">Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Community-acquired pneumonia in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=community-acquired-pneumonia-in-children-outpatient-treatment\" class=\"medical medical_review\">Community-acquired pneumonia in children: Outpatient treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=continuous-oxygen-delivery-systems-for-infants-children-and-adults\" class=\"medical medical_review\">Continuous oxygen delivery systems for infants, children, and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-treatment-and-prevention-of-adenovirus-infection\" class=\"medical medical_review\">Diagnosis, treatment, and prevention of adenovirus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=flexible-bronchoscopy-in-adults-indications-and-contraindications\" class=\"medical medical_review\">Flexible bronchoscopy in adults: Indications and contraindications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-metapneumovirus-infections\" class=\"medical medical_review\">Human metapneumovirus infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maintenance-fluid-therapy-in-children\" class=\"medical medical_review\">Maintenance fluid therapy in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">Management and prognosis of parapneumonic effusion and empyema in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycoplasma-pneumoniae-infection-in-children\" class=\"medical medical_review\">Mycoplasma pneumoniae infection in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">Neonatal pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=parainfluenza-viruses-in-children\" class=\"medical medical_review\">Parainfluenza viruses in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumonia-in-children-the-basics\" class=\"medical medical_basics\">Patient education: Pneumonia in children (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children\" class=\"medical medical_review\">Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-pneumonia-in-children\" class=\"medical medical_review\">Pneumococcal pneumonia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumonia-caused-by-chlamydia-species-in-children\" class=\"medical medical_review\">Pneumonia caused by Chlamydia species in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumonia-in-children-epidemiology-pathogenesis-and-etiology\" class=\"medical medical_review\">Pneumonia in children: Epidemiology, pathogenesis, and etiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-syncytial-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Respiratory syncytial virus infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-syncytial-virus-infection-treatment\" class=\"medical medical_review\">Respiratory syncytial virus infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Seasonal influenza in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">Seasonal influenza in children: Prevention and treatment with antiviral drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-pediatric-pneumonia\" class=\"medical medical_society_guidelines\">Society guideline links: Pediatric pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-common-cold-in-children-management-and-prevention\" class=\"medical medical_review\">The common cold in children: Management and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization\" class=\"medical medical_review\">Treatment of community-acquired pneumonia in adults who require hospitalization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection\" class=\"medical medical_review\">Treatment of varicella (chickenpox) infection</a></li></ul></div></div>","javascript":null}